Detalles de la búsqueda
1.
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
BMC Cancer
; 16: 147, 2016 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26911310
2.
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
Medicine (Baltimore)
; 96(15): e6518, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28403082
3.
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Am J Clin Oncol
; 39(4): 355-62, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24710123
4.
Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
J Thorac Oncol
; 8(9): 1148-55, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23945384
Resultados
1 -
4
de 4
1
Próxima >
>>